UpFront key facts
as of Oct 2026- Developer of rapid diagnostic tests designed for stroke identification.
- UpFront is valued at approximately $36.5M as of Oct 2026 (last reported valuation).
- It has raised $7.1M.
- Notable investors include Innovate UK, Accelerate Cambridge, APEX Ventures, Creator Fund, PanaceaStars — 9 tracked in total.
- Status: Privately Held (backing).
UpFront's last reported valuation, May 2025. Nothing priced has surfaced since.
- ·Watch UpFront: the Monday email on marks, rounds and moves
UpFront funding rounds
No funding rounds for UpFront are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
UpFront valuation
UpFront's last reported valuation was $36.5 million in May 2025. No priced round, secondary trade or fund mark has surfaced since.
UpFront investors
9 investors are on record for UpFront, including Innovate UK, Accelerate Cambridge, APEX Ventures and Creator Fund.
About UpFront
Developer of rapid diagnostic tests designed for stroke identification. The company uses blood biomarkers to detect large vessel occlusion strokes within minutes with high accuracy and single-drop blood tests to identify large vessel occlusion (LVO) strokes in emergency settings, enabling emergency medical professionals, clinicians, paramedics, and nurses to deliver faster and more accurate diagnoses, improving patient outcomes, and reducing healthcare costs.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2017
- Employees
- 8
- Website
- upfrontdiagnostics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.